Abstract：
:The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian insufficiency (POI) and infertility. Assisted reproductive technologies (ART) can address infertility, but fail to preserve the natural function of the ovaries as a source of hormones that regulate many aspects of women's health. The advancement of fertoprotective technologies is hindered by our lack of understanding of oocyte biology and their sensitivity to cancer therapies. Because many cancer treatments cause DNA damage, apoptosis is thought to be the major mechanism eliminating damaged oocytes. Indeed, recent studies in mice demonstrate that targeting proteins involved in apoptosis protects oocytes and prevents infertility in females exposed to radiation. Therefore, a better appreciation of oocyte response to radiation and anticancer drugs will uncover new targets for the development of specialized therapies to prevent ovarian failure. We make a case here for the necessity of such fertoprotective treatments. We review recent findings that have significantly advanced our understanding of how cancer therapies induce apoptotic death in oocytes, and how we could use this knowledge to design better fertoprotective treatments.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Woodard TL,Bolcun-Filas Edoi
10.1016/j.trecan.2016.03.006subject
Has Abstractpub_date
2016-05-01 00:00:00pages
222-233issue
5eissn
2405-8033issn
2405-8025pii
S2405-8033(16)30001-2journal_volume
2pub_type
杂志文章,评审相关文献
Trends in Cancer文献大全abstract：:The regulation of immune responses by tumors is central to their survival. By diminishing the production of interferon (IFN) and other inflammatory mediators, tumors enhance immune evasion. Responses initiated by nucleic acid sensors and triggered by dysregulated RNA transcription and cytoplasmic DNA undergo down-modu...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.03.004
更新日期：2019-05-01 00:00:00
abstract：:Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.02.012
更新日期：2020-05-01 00:00:00
abstract：:The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.03.004
更新日期：2017-04-01 00:00:00
abstract：:Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immuno...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.09.001
更新日期：2018-11-01 00:00:00
abstract：:Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.08.005
更新日期：2019-10-01 00:00:00
abstract：:Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.11.006
更新日期：2020-12-09 00:00:00
abstract：:Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.11.007
更新日期：2020-12-16 00:00:00
abstract：:Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.11.004
更新日期：2018-01-01 00:00:00
abstract：:In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.05.014
更新日期：2020-09-01 00:00:00
abstract：:Neutrophil extracellular traps (NETs) have emerged as significant contributors to cancer-associated pathologies such as metastasis, thrombosis, and organ dysfunction in preclinical models. We review recent discoveries of the involvement of NETs in human cancers and suggest tumor-induced NET formation as an interesting...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.10.012
更新日期：2016-11-01 00:00:00
abstract：:The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.12.004
更新日期：2018-02-01 00:00:00
abstract：:Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research ha...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.06.005
更新日期：2020-11-01 00:00:00
abstract：:Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.02.022
更新日期：2020-07-01 00:00:00
abstract：:Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.07.002
更新日期：2016-08-01 00:00:00
abstract：:The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.11.001
更新日期：2016-12-01 00:00:00
abstract：:TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.01.007
更新日期：2020-02-01 00:00:00
abstract：:In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2019.10.004
更新日期：2019-12-01 00:00:00
abstract：:Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.12.003
更新日期：2021-02-01 00:00:00
abstract：:Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.02.014
更新日期：2020-06-01 00:00:00
abstract：:Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.08.003
更新日期：2016-09-01 00:00:00
abstract：:Targeted therapy has become increasingly important in cancer therapy. For example, targeting the promyelocytic leukemia PML protein in leukemia has proved to be an effective treatment. PML is the core component of super-assembled structures called PML nuclear bodies (NBs). Although this nuclear megaDalton complex was ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.05.005
更新日期：2020-10-01 00:00:00
abstract：:Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.01.010
更新日期：2020-04-01 00:00:00
abstract：:Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.10.005
更新日期：2018-12-01 00:00:00
abstract：:Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer. ...
journal_title：Trends in cancer
pub_type： 信件
doi：10.1016/j.trecan.2018.12.005
更新日期：2019-03-01 00:00:00
abstract：:Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.01.003
更新日期：2017-03-01 00:00:00
abstract：:Precision medicine requires appropriate application of genomics in clinical practice. In cancer, we have witnessed practice-changing examples of how genomic knowledge is translated into more tailored and effective therapies. The next opportunity is to embed cancer genomics in clinical context so that patient-centric l...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2015.07.010
更新日期：2015-09-01 00:00:00
abstract：:In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2015.12.003
更新日期：2016-01-01 00:00:00
abstract：:The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.01.002
更新日期：2016-02-01 00:00:00
abstract：:The liver is one of the major metabolic organs in the body, susceptible to injury caused by various factors. In response to injury, sophisticated mechanisms are engaged to repair and regenerate the damaged liver, preventing its failure. When the damage is chronic, regeneration goes awry, impairing liver function and c...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.08.005
更新日期：2021-01-01 00:00:00
abstract：:Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.01.004
更新日期：2018-03-01 00:00:00
